Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

September 17th, 2026

Q&A with Dr. Athenecia Faggins: Practical Challenges in Raw Material Management for Advanced Therapies

Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.

FDA drug approval process, pharmaceutical regulatory compliance, food and drug administration certification, medical product approval concept, drug testing and approval | image credit: © Сергей Шиманович - © Сергей Шиманович - stock.adobe.com

September 17th, 2026

CBER, CDER Compliance Leaders Outline 2026 Guidance Shifts and Rising GMP Violations

FDA compliance officers detailed 2026 guidance updates, online drug sale enforcement, and a first-of-its-kind AI-related warning letter at the PDA/FDA Joint Regulatory Conference.

September 17th, 2026

Q&A with Dr. Jack Prior: Is Your Process Data Ready to Act On?

Sanofi’s Jack Prior discusses how biopharmaceutical manufacturers can assess whether process data is ready for human and AI use, and the role of data quality, accessibility, governance, and AI in manufacturing.

Global shipping and supply chain vector illustration. Abstract concept with world map background and connected icons related to international import / export, distribution and transportation. | Image credit: © j-mel - © j-mel - stock.adobe.com

September 17th, 2026

FDA, Genentech, Minaris Panelists Detail Raw Material Risk Strategies for Advanced Therapies

Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.

3d rendering of Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously. | Image credit: © Love Employee - © Love Employee - stock.adobe.com

September 17th, 2026

Dualitas Partners With Roche on Bispecific Antibody Discovery

Dualitas will screen over 300,000 bispecific combinations for Roche, backing a deal worth up to $1 billion in immunology research.

September 16th, 2026

CDER, CBER Officials Outline GMP Compliance Trends

FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.

Global health safety regulation Concept, Businesswoman reviewing and approving FDA standard documents for medical and food, Compliance, laboratory inspection, certification, and international approval | Image credit: © Ticha - © Ticha - stock.adobe.com

September 16th, 2026

FDA, Sanofi, Gilead Weigh AI Readiness and Validation Risk at PDA/FDA Conference

Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.

Team of Research Scientists in Sterile Suits Working with Computers, Microscopes and Modern Industrial Machinery in the Laboratory. Product Manufacturing Process: Pharmaceutics, Biotechnology. | Image credit: © Gorodenkoff - © Gorodenkoff - stock.adobe.com

September 16th, 2026

FDA Highlights Aseptic Processing Pitfalls at PDA/FDA Conference

FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.